FDA OTAT Launches Gene Therapy CMC Town Hall Series to Guide IND and BLA Submissions

For advanced therapy manufacturers building out gene therapy programs, FDA's Office of Tissues and Advanced Therapies (OTAT) has signaled a more structured engagement posture on chemistry, manufacturing, and controls, one that carries direct implications for how sponsors document CMC commitments in IND, BLA, and NDA submissions.

OTAT, operating under CBER, hosted the first in a planned virtual town hall series on September 22, 2022, dedicating the inaugural session to gene therapy CMC. Subject matter experts from the Division of Cell and Gene Therapy fielded stakeholder questions in a Q&A format, with the stated objective of providing regulatory clarity to advance drug development. A transcript is available as a 370.92 KB PDF through the event page.

The CMC expectations OTAT addressed are not new in principle: sponsors must demonstrate a manufacturing and testing commitment that assures product safety, identity, quality, purity, and potency, consistent with longstanding biologics requirements. What the town hall format adds is a direct line to OTAT reviewers on how those expectations translate into gene therapy-specific submissions, where manufacturing complexity and novel modalities routinely generate interpretive questions during IND and BLA review cycles.

For QA directors and regulatory leads, the practical read is around submission architecture. Gene therapy CMC packages must substantiate the sponsor's control strategy across the full product lifecycle, and OTAT's willingness to engage publicly on these questions suggests the agency is aware that interpretive gaps exist. The town hall transcript provides a reference point for teams calibrating their CMC narratives ahead of pre-IND meetings or BLA filing timelines.

One structural constraint is worth noting: OTAT confirmed it cannot address questions about specific investigational products or active drug applications during town hall sessions, limiting the forum to general regulatory guidance rather than product-specific counsel. Sponsors seeking application-specific input remain dependent on formal meeting requests through established FDA channels.

The September 2022 session was explicitly framed as the first in a series, with future topics to span the broader range of OTAT-regulated products. Teams tracking the series through the CBER listserv or events calendar will have advance visibility into upcoming CMC and non-CMC sessions as OTAT expands the program.

The availability of the session transcript gives regulatory affairs leads a concrete reference document for benchmarking internal CMC documentation standards against OTAT's stated expectations ahead of the next submission cycle.

Source: FDA CBER / OTAT via FDA.gov (Vaccines, Blood & Biologics), event held September 22–29, 2022; transcript available as PDF (370.92 KB).